S. Polyakov

1.5k total citations · 1 hit paper
20 papers, 940 citations indexed

About

S. Polyakov is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, S. Polyakov has authored 20 papers receiving a total of 940 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 7 papers in Surgery and 6 papers in Oncology. Recurrent topics in S. Polyakov's work include Prostate Cancer Treatment and Research (7 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Bladder and Urothelial Cancer Treatments (5 papers). S. Polyakov is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Bladder and Urothelial Cancer Treatments (5 papers). S. Polyakov collaborates with scholars based in Belarus, United States and Finland. S. Polyakov's co-authors include Neal D. Shore, Murilo Luz, Teuvo L.J. Tammela, Toni Sarapohja, Karim Fizazi, Mindaugas Jievaltas, B. Yа. Alekseev, Egils Vjaters, Albertas Ulys and Amir Snapir and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

S. Polyakov

17 papers receiving 930 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

2019 579 citations Karim Fizazi, Neal D. Shore et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Polyakov Belarus	8	811	281	273	180	153	20	940
Murilo Luz Brazil	7	952 1.2×	324 1.2×	303 1.1×	199 1.1×	175 1.1×	34	1.1k
Giri Sulur United States	8	587 0.7×	199 0.7×	216 0.8×	159 0.9×	189 1.2×	19	796
Sharon McCarthy United States	8	962 1.2×	326 1.2×	341 1.2×	217 1.2×	175 1.1×	28	1.1k
Per Rathenborg Denmark	11	923 1.1×	325 1.2×	308 1.1×	309 1.7×	182 1.2×	18	1.1k
Álvaro Juárez Soto Spain	8	1.1k 1.3×	345 1.2×	379 1.4×	222 1.2×	201 1.3×	44	1.2k
Valentina Bertaglia Italy	13	536 0.7×	284 1.0×	218 0.8×	417 2.3×	119 0.8×	36	905
Kris Deprince United States	7	948 1.2×	312 1.1×	333 1.2×	252 1.4×	167 1.1×	15	1.2k
Erik Briers Belgium	5	1.1k 1.4×	223 0.8×	445 1.6×	233 1.3×	97 0.6×	7	1.3k
S. Chowdhury United Kingdom	16	699 0.9×	291 1.0×	242 0.9×	267 1.5×	91 0.6×	58	951
Vahid Naini United States	8	1.1k 1.3×	357 1.3×	417 1.5×	244 1.4×	191 1.2×	21	1.2k

Countries citing papers authored by S. Polyakov

Since Specialization

Citations

This map shows the geographic impact of S. Polyakov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Polyakov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Polyakov more than expected).

Fields of papers citing papers by S. Polyakov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Polyakov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Polyakov. The network helps show where S. Polyakov may publish in the future.

Co-authorship network of co-authors of S. Polyakov

This figure shows the co-authorship network connecting the top 25 collaborators of S. Polyakov. A scholar is included among the top collaborators of S. Polyakov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Polyakov. S. Polyakov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gabai, Vladimir L., et al.. (2025). Efficacy of P62-expressing plasmid in treatment of canine osteoarthritis pain: a pilot study. Frontiers in Veterinary Science. 12. 1519881–1519881.

Polyakov, S., et al.. (2024). Clinical efficacy of plasmid encoding p62/SQSTM1 (Elenagen) in combination with gemcitabine in patients with platinum-resistant ovarian cancer: a randomized controlled trial. Frontiers in Oncology. 14. 1343023–1343023. 3 indexed citations

Shneider, Alexander, et al.. (2023). Effects of the baseline prognostic factors on efficacy of the p62/SQSTM1-encoding plasmid combined with gemcitabine in patients with recurrent platinum-resistant ovarian cancer.. Journal of Clinical Oncology. 41(16_suppl). e17540–e17540. 1 indexed citations

Bögemann, Martin, Neal D. Shore, Matthew R. Smith, et al.. (2022). Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial. European Urology. 83(3). 212–221. 7 indexed citations

Smith, Matthew R., Neal D. Shore, Teuvo L.J. Tammela, et al.. (2021). Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. European Journal of Cancer. 154. 138–146. 23 indexed citations

Schmeler, Kathleen M., et al.. (2021). Pelvic Exenteration in Patients with Persistent and Recurrent Cervical Cancer: A Case Series from Belarus. 6(1). 1–9. 1 indexed citations

Polyakov, S., et al.. (2021). 759P Adding dosing of plasmid encoding p62/SQSTM1 to gemcitabine chemotherapy may provide clinical benefits to patients with platinum-resistant ovarian cancer. Annals of Oncology. 32. S747–S748. 2 indexed citations

Polyakov, S., et al.. (2021). 278P Plasmid encoding p62/SQSTM1 administered in combination with CMF chemotherapy improves outcomes in metastatic triple-negative breast cancer patients. Annals of Oncology. 32. S485–S485. 2 indexed citations

Fizazi, Karim, Neal D. Shore, Teuvo L.J. Tammela, et al.. (2020). 223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC). Annals of Oncology. 31. S1328–S1328. 2 indexed citations

10.

Polyakov, S., et al.. (2020). Long-term results of a single-center prospective randomized trial assessing efficacy of a shortened course of adjuvant chemotherapy after radical cystectomy in patients with locally advanced bladder cancer. Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication. 73(1). 26–32. 9 indexed citations

11.

Fizazi, Karim, Neal D. Shore, Teuvo L.J. Tammela, et al.. (2020). Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. New England Journal of Medicine. 383(11). 1040–1049. 225 indexed citations

12.

Fizazi, Karim, Neal D. Shore, Teuvo L.J. Tammela, et al.. (2020). Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology. 38(15_suppl). 5514–5514. 31 indexed citations

13.

Fizazi, Karim, Neal D. Shore, Teuvo L.J. Tammela, et al.. (2019). Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. New England Journal of Medicine. 380(13). 1235–1246. 579 indexed citations breakdown →

14.

Polyakov, S., et al.. (2019). Trends in incidence, mortality and survival of testicular cancer patients in Belarus. Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication. 72(4). 357–368.

15.

Fizazi, Karim, Neal D. Shore, Teuvo L.J. Tammela, et al.. (2019). ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology. 37(7_suppl). 140–140. 6 indexed citations

16.

Polyakov, S., et al.. (2019). Efficacy of fluorescent cystoscopy-assisted transurethral resection in patients with non-muscle invasive bladder cancer and quality of surgery: post-hoc analysis of а prospective randomized study. Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication. 72(4). 351–356. 2 indexed citations

17.

Polyakov, S., et al.. (2017). Long-term benefit of fluorescent cystoscopy-assisted transurethral resection in patients with non-muscle invasive bladder cancer is dependent on quality of surgery. European Urology Supplements. 16(5). e2236–e2236.

18.

Andrushchuk, Uladzimir, et al.. (2017). Simultaneous or staged surgery in patients with kidney tumors and concomitant cardiac disease. Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication. 70(4). 356–361. 2 indexed citations

19.

Polyakov, S., et al.. (2016). Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer. World Journal of Urology. 35(5). 745–752. 28 indexed citations

20.

Polyakov, S., et al.. (2016). Surgeon has a major impact on long-term recurrence risk in patients with non-muscle invasive bladder cancer. Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication. 69(2). 170–7. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact